We conducted phase I , open-label , single-centre studies in healthy male volunteers who received a single once-daily oral dose of afatinib ( 20 or 40 mg ) together with either ritonavir or rifampicin ; two studies had a randomised , two - and three-way crossover design and the third was a non-randomised , two-period sequential study .